Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

March 2008

June 25th 2010

The Academy delivers the latest news on biotech and oncoloy research, providing a link between the clinical world of cancer care and the university researchers who are pushing the envelope of knowledge and discovery.

Lenalidomide (Revlimid) Plus Dexamethasone Compared with Dexamethasone Alone in Patients with Newly Diagnosed Multiple Myeloma

May 25th 2010

In an oral presentation, Jeffrey A. Zonder, MD, Division of Hematology-Oncology, Karmanos Cancer Center, Wayne State University School of Medicine,Detroit, Michigan, reported updated results of SWOG 0232, a study of lenalidomide (Revlimid) plus dexamethasone compared with dexamethasone alone in patients with newly diagnosed multiple myeloma (MM).

50th Annual Meeting of the American Society of Hematology

January 27th 2009

Highlights from the 50th Annual Meeting of the American Society of Hematology.